MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 7.4
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 7.4 (MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 7.4).
Provides essential electrolytes (calcium, magnesium, potassium, sodium, acetate, chloride) to maintain or restore electrolyte balance, acid-base equilibrium, and osmotic pressure in extracellular fluid. Calcium and magnesium are critical for neuromuscular function and enzymatic reactions. Acetate is metabolized to bicarbonate in the liver and peripheral tissues, serving as an alkalinizing agent to correct acidosis.
| Metabolism | Acetate is metabolized to bicarbonate in the liver and peripheral tissues via acetyl-CoA and the Krebs cycle. Electrolytes (calcium, magnesium, potassium, sodium, chloride) are not metabolized and are excreted primarily renally, with minor losses via feces and sweat. |
| Excretion | Renal: >95% as infused electrolytes via glomerular filtration and tubular handling. Biliary/fecal: <5% in normal renal function. |
| Half-life | Not applicable as components are endogenous; exogenous electrolytes have functional half-lives of minutes to hours depending on compartment equilibration. |
| Protein binding | Negligible (<5%); electrolytes are free ions in plasma. |
| Volume of Distribution | Varies by ion: Na+ ~0.5 L/kg (extracellular), K+ ~4 L/kg (intracellular), Cl- ~0.3 L/kg. Overall composite Vd ~0.2-0.5 L/kg. |
| Bioavailability | Intravenous: 100% (complete). |
| Onset of Action | Intravenous: Immediate (within seconds) as electrolytes distribute directly into vascular compartment. |
| Duration of Action | Intravenous: 1-4 hours for acute correction of deficits; sustained effect requires continuous infusion or repeated doses. |
Intravenous infusion; dose determined by individual electrolyte requirements and fluid status. Typical adult dose: 500-1000 mL as a continuous infusion at a rate of 100-200 mL/hour, not to exceed 3 L/day.
| Dosage form | INJECTABLE |
| Renal impairment | GFR 30-50 mL/min: Reduce infusion rate by 50%; monitor serum electrolytes closely. GFR <30 mL/min: Avoid use due to risk of hyperkalemia and hyperphosphatemia; use alternative electrolyte preparation. |
| Liver impairment | Child-Pugh Class C: Avoid use due to risk of fluid overload and electrolyte imbalances; consider alternative with lower volume and adjusted electrolyte content. |
| Pediatric use | Weight-based: 20-40 mL/kg/day as continuous infusion; adjust rate based on serum electrolytes and fluid balance. Maximum infusion rate: 100 mL/hour. |
| Geriatric use | Use with caution due to age-related decline in renal function. Start at lower infusion rate (50-100 mL/hour) and monitor electrolytes, fluid balance, and cardiac function closely. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 7.4 (MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 7.4).
| Breastfeeding | Excreted into human milk; electrolytes equilibrate with maternal serum. M/P ratio not established. Compatible with breastfeeding when used at physiologic doses; monitor infant for electrolyte disturbances if maternal serum levels are abnormal. |
| Teratogenic Risk | No studies in pregnant women; animal reproduction studies not conducted. Contains electrolytes at physiologic concentrations: sodium 140 mEq/L, potassium 5 mEq/L, calcium 2.5 mEq/L, magnesium 1.5 mEq/L, chloride 98 mEq/L, acetate 27 mEq/L, gluconate 23 mEq/L. No known teratogenic effects at therapeutic doses. Risk of electrolyte imbalance if administered inappropriately. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hyperkalemia","Hypercalcemia","Hypermagnesemia","Hypernatremia","Patients with severe renal impairment (oliguria, anuria) unless dialysis is used","Patients with metabolic alkalosis","Concurrent use of digoxin (increased risk of arrhythmias due to calcium)","Do not administer to patients with known hypersensitivity to any component"]
| Precautions | ["Risk of fluid and/or solute overload leading to dilution of serum electrolyte concentrations, overhydration, congested states, or pulmonary edema","Risk of aluminum toxicity in patients with impaired renal function due to aluminum content of the injection","Avoid rapid administration of calcium-containing solutions to prevent hypercalcemia and cardiac arrhythmias","Monitor serum electrolytes, renal function, and acid-base balance during therapy","Use with caution in patients with heart failure, renal impairment, or conditions predisposing to hyperkalemia (e.g., burns, severe trauma) due to potassium content","Do not use if solution is discolored or contains precipitate; use administration set with filter"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal serum electrolytes (Na, K, Ca, Mg, Cl, bicarbonate), renal function, fluid balance, and ECG during prolonged therapy. Fetal monitoring via ultrasound for signs of hydrops or arrhythmias if maternal electrolyte disturbances occur. |
| Fertility Effects | No known adverse effects on fertility at recommended doses. Severe electrolyte disturbances may impair reproductive function. |